RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Investor Presentation (May 2015)
30 slides from RespireRx Pharmaceuticals's investor presentation, May 1, 2015
Slide 1: Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc. May 4, 2015
Slide 2: Forward-looking statements
PHARMACEUTICALS, INC. ia (CRTEX The matters discussed in this presentation that are not historical facts are "forward- looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "expects," "projects" and word
Slide 3: Background
Background 2013 * Insolvent & near bankruptcy No ongoing operations Lost dronabinol license Deficient in SEC reporting Approx. $3M market cap Today + Non-bankruptcy reorganization New capital raised Re-gained dronabinol license Current in SEC reporting Approx. $25M market cap + Newly organized resea
Slide 4: Management and Directors
Management and Directors Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell John Greer Katie MacFarlane James Sapirstein Chairman, CEO VP, Sec/Treas, Director CFO, Director Senior VP R&D Chairman, Scientific Advisory Board Prof & Dir. Neuroscience Ctr., U. Alberta Director, CCO Agile Thera
Slide 5: Cortex Drug Platforms
Cortex Drug Platforms Ampakines * Positive allosteric modulators of AMPA glutamate receptors + Positive effects for treatment of drug-induced respiratory depression in Phase 2A studies * Positive effects for treatment of central sleep apnea in Phase 2A study + Positive effects for treatment of ADHD
Slide 6: Key Company Highlights
Cortex is a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders Key Company Highlights Drug-induced respiratory depression (RD) - ampakines ° Acute use —- surgical anesthesia with propofol ° Semi-acute use — post-surgical pain management wit
Slide 7: Large Market with Unmet Need
a leader je discovery and development of innovative maceuticals for the treatment of breathing disorders Large Market with Unmet Need + Drug-Induced Respiratory Depression (RD) - Patients treated with anesthetic, analgesic and/or sedatives in association with surgery (12 million/yr) or medical proce
Slide 8: AMPAKINES - Positive Allosteric Modulators at AMPA Glutamate Receptors
AMPAKINES - Positive Allosteric Modulators at AMPA Glutamate Receptors AMPA Receptors Mediate Synaptic Transmission in the Brain » Glutamate is the major excitatory ya neurotransmitter in the CNS . . ° » Fast excitatory transmission is mediated by AMPA-type glutamate receptors » Ampakines are positi
Slide 9: AMPAKINES - Novel Treatment for Respiratory Depression
AMPAKINES - Novel Treatment for Respiratory Depressio Initial research conducted by Dr. J. Greer, U. Alberta Ren et al, Anesthesiology. 110:1364-1370, 2009 PreBétzinger Complex Xil motor output Neurons in this brainstem region control inspiratory breathing rhythm PreBotC neurons use AMPA receptors f
Slide 10: Acute Drug-induced Respiratory Depression
Acute Drug-induced Respiratory Depression * Most frequent lethal side effect of opiate use is respiratory depression (RD) * In-patient, peat gical opiate use (~12M patients/year) increases risk for R * RD also occurs during anesthetic procedures (e.g. colonoscopy) with propofol (20 MM procedures/yea
Slide 11: CX1739: An Oral Phase 2 Ampakine
CX1 739: An Oral Phase 2 Ampakine » Stage of Development ° Completed Phase 1 in healthy volunteers and Phase 2a in central sleep apnea e Ready for Phase 2A studies in opiate- and propofol-induced respiratory depression and central sleep apnea » Targeted Indication e Prevention of propofol-induced re
Slide 12: Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats
Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats CX1739 injection _Fentanyl Fentanyl f I ll. enn {i cette marina etnttisetaneeenrt = 10s Prolonged opiate-induced CX1739 reverses opiate-induced respiratory depression leads to respiratory depression and lethality prevents let
Slide 13: Reversal of Propofol-induced RD With an Ampakine in the Rat
Reversal of Propofol-induced RD With an Ampakine in the Rat Experimental Design: - Administer a lethal dose of propofol to rats - Inject CX1739 within 1 minute Propofol a Propofol + CX1739 TT an 13
Slide 14: Depression in Humans
Deprescion'l in Hum as Two clinical studies were run in normal, healthy volunteers with CX717, an earlier Ampakine Moderate respiratory depression was induced experimentally by infusion of the opioid, Alfentanil Respiratory and analgesia end-points were measured
Slide 15: CX717 respiratory rate data
CPlacebo Gg CX717 NORMAL ~~" — *P<0.01 RD < 8 BPM---§& NS - Not Significant $ o Baseline +Alfentanil +Naloxone Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. 15
Slide 16: CX717 pain sensitivity data
(Placebo B 15 mmgcx717 2 = 2 40 NS 3B —_ Delivery of a electrical & stimulation to finger a 05. 0.0 Baseline _+Alfentanil__+Naloxone Data are expressed as the pain sensitivity, normalized to the Baseline measurement. N = 15 and 16 per group. CX717 dose is 1500mg. 16
Slide 17: Pompe Disease
POMPE DISEASE Autosomal recessive metabolic disorder caused by an accumulation of lysosomal glycogen due to a deficiency of alpha glucosidase *« Damages muscle and nerve cells throughout the body + Respiratory failure is the most common cause of death * Replacement enzyme therapy _
Slide 18: Mouse Model of Pompe Disease
MOUSE MODEL OF POMPE DISEASE Effects of Ampakine on Minute Volume 20 " * ‘5 — 15 4 I 1 E 10 th Gaa” Wild-type = 15 mgikg == 30mg/kg * p<.05, compared to vehicle ** p<.05, compared to mutant Elmallah et al, in press 18
Slide 19: CX1942: A Soluble AMPA-PAM
CX1942: A Soluble AMPA-PAM » Mechanism of Action ° A Positive Allosteric Modulator of AMPA receptors (AMPA-PAM) ° Water-soluble for injectable dosage forms » Stage of Development e Injectable routes being studied in animal models of respiratory depression ° Supported by SBIR contract » Targeted Indi
Slide 20: Sleep Apnea
Sleep Apnea ° Repetitive episodes of airflow cessation apnea) or reduction (hypopnea) for more than 10s during sleep e Three types: Obstructive, Central & Mixed The Sleep Apnea Market is Large ° 18 million U.S. adults with moderate or severe sleep apnea ° Market potential for sleep apnea is $3 - 9 B
Slide 21: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) » Obstructive sleep apnea (OSA) involves a decrease or complete halt in airflow despite an ongoing effort to breathe during sleep ° Occurs when the muscles relax during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Affects 18 MM adults in
Slide 22: Obstructive Sleep Apnea: Scope of the Problem in the US
Obstructive Sleep Apnea Scope of the Problem in the US Estimated Disease State US Prevalence Annual Estimated Cost to Society Annual Indicated Drug Therapy Expenditures OSAt> 18.0 MM $75.0 Billion $0 Asthma®7 16.4 MM $18.3 Billion $13.5 Billion Hypertension®?°| 43.2 MM $73.4 Billion $48.5 Billion Di
Slide 23: CPAP Efficacy is Greatly Limited by Patient Compliance
CPAP Efficacy is Greatly Limited by Patient Compliance Works as an air splint to keep upper airway open during sleep 30% of patients prescribed CPAP never initiate treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year of use ; may only wear 3-4h/ night ya yp si j
Slide 24: Dronabinol for Treatment of OSA: A Phase 2 Compound
Dronabinol for Treatment of OSA: A Phase 2 Compound Mechanism of Action ° Dronabinol is (A-9)THC, a cannabinoid agonist v Commercial Status ° FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy ° Schedule III drug available b
Slide 25: Dronabinol Phase 2A Clinical Study in OSA
Dronabinol Phase 2A Clinical Study in OSA » Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA » Randomized to Placebo (N=5) or Dronabinol (N=17) for 21 days ° 2.5, 5 and 10 mg/night studied with weekly dose escalation >» Overnight polysomnogram (PSG) at basel
Slide 26: Dronabinol Reduced the AHI in OSA Subjects
Dronabinol Reduced the AHI in OSA Subjects AHI Mean % Change from Baseline to End of Treatment Dronabinol Placebo Reduction in Sleep Apnea P<0.01 -40% Rr +
Slide 27: AAHI versus Baseline as a Function of Dose
AAHI versus Baseline in as a Function of Dose ai Apnea Suppres: n=17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. wi Ist Half 2nd Half a
Slide 28: Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea
Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea ° Phase 2B study in progress at University of Illinois ° 120 subjects (40/group, 6 wks dosing) ° Doses: Placebo, 2.5 mg, 10 mg qd ° Study costs funded by NIH Grant for $5 MM ° Top line data by 3Q2015 |
Slide 29: Protecting Dronabinol in the Marketplace
Protecting Dronabinol in the Marketplace » Issued Method-of-Use patent for dronabinol and OSA ° Expires in 2025 » Potential proprietary dosage and pulse-dose formulation to provide efficacy over entire night ° Pending patent applications » US government maintains close oversight on off-label dronabi
Slide 30: Objectives for Next Months
Objectives for Next 12 Mon Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase IIB started 3Q2015 iate-induced RD Phase IIA 2Q2015 3Q2015 CX1739 = = = Propofol-induced RD Phase IIA 3Q2015 4Q2015 CX1739/ é hase ITA CXx717 Pompe Disease Phase 4
Cortex Pharmaceuticals — Investor Presentation (May 2015) on 6ix